PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
NCT06186609
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
68
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG:
PD-1 inhibitor 200mg per three to four weeks, for one year
Sponsor
Affiliated Hospital of Nantong University